Clinical Trials

38 studies in Nephrology and Hypertension

  1. An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
    1. Arizona
  2. Biobank Protocol, Rare Diseases Clinical Research Network
    1. Minnesota
  3. A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
    1. Minnesota
  4. "A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)"
    1. Arizona,
    2. Florida,
    3. Minnesota
  5. A Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument
    1. Minnesota
  6. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor
    1. Arizona
  7. Influence of Hydroxyproline Plasma Concentration on Its Metabolism to Oxalate
    1. Minnesota
  8. Systematic Review of Clinical Biopsies of Dent Disease Patients
    1. Minnesota
  9. Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
    1. Minnesota
  10. An Open-Label Study to Explore the Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching When Used for Treatment of Group 1 Pulmonary Arterial Hypertension in Patients With Concomitant Chronic Obstructive Pulmonary Disease (COPD)
    1. Florida
  1. Prev
  2. 1
  3. 2
  4. 3
  5. 4
  6. Next

Clinical Trials

38 studies in Nephrology and Hypertension

  1. An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
    1. Arizona
  2. Biobank Protocol, Rare Diseases Clinical Research Network
    1. Minnesota
  3. A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
    1. Minnesota
  4. "A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)"
    1. Arizona,
    2. Florida,
    3. Minnesota
  5. A Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument
    1. Minnesota
  6. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor
    1. Arizona
  7. Influence of Hydroxyproline Plasma Concentration on Its Metabolism to Oxalate
    1. Minnesota
  8. Systematic Review of Clinical Biopsies of Dent Disease Patients
    1. Minnesota
  9. Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
    1. Minnesota
  10. An Open-Label Study to Explore the Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching When Used for Treatment of Group 1 Pulmonary Arterial Hypertension in Patients With Concomitant Chronic Obstructive Pulmonary Disease (COPD)
    1. Florida
  1. Prev
  2. 1
  3. 2
  4. 3
  5. 4
  6. Next
.

Mayo Clinic Footer